IRD vs LIN · rev $11.0M vs P/E 34, rev $33.99B
Opus Genetics, Inc. (IRD) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Opus Genetics, Inc. (IRD) is a biotechnology company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported IRD revenue for 2024-12-31 was $11.0M. Net income was -$57.5M. Revenue was down 42.3% from 2023-12-31 to 2024-12-31. IRD currently screens at market cap $35.7M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
IRD currently screens at market cap $35.7M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the IRD and LIN stock pages for the full models.
Not investment advice.